Current and investigational drug strategies for glioblastoma

Clinical Oncology

Volumn 26, Issue 7, 2014, Pages 419-430

  Ajaz, M ^a   Jefferies, S ^b   Brazil, L ^c   Watts, C ^d   Chalmers, A ^e  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chemotherapy; Clinical trials; Glioblastoma multiforme; New agents

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BENDAMUSTINE; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CARBOPLATIN; CEDIRANIB; DOVITINIB; ENZASTAURIN; ETOPOSIDE; FOTEMUSTINE; IRINOTECAN; LAPATINIB PLUS PAZOPANIB; LENVATINIB; LINIFANIB; LOMUSTINE; MOTESANIB; NINTEDANIB; PACLITAXEL POLIGLUMEX; PROCARBAZINE; PROTEIN TYROSINE KINASE; REGORAFENIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TIVOZANIB; VANDETANIB; VASCULOTROPIN RECEPTOR; VINCRISTINE; NEW DRUG;

ADD ON THERAPY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG INHIBITION; DRUG RESEARCH; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BRAIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUGS, INVESTIGATIONAL; GLIOBLASTOMA; HUMANS;

EID: 84902106753     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.03.012     Document Type: Article

References (183)

1. Ciriello G., Miller M.L., Aksoy B.A., Senbabaoglu Y., Schultz N., Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013, 45:1127-1133.
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEngl J Med 2005, 352:987-996.
3. Chinot O.L., Wick W., Mason W., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. NEngl J Med 2014, 370:709-722.
4. Gilbert M.R., Dignam J.J., Armstrong T.S., et al. Arandomized trial of bevacizumab for newly diagnosed glioblastoma. NEngl J Med 2014, 370:699-708.
5. Shapiro W.R., Young D.F. Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride. Trans Am Neurol Assoc 1976, 101:217-220.
6. van den Bent M.J., Brandes A.A., Taphoorn M.J., et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. JClin Oncol 2013, 31:344-350.
7. Shaw E.G., Wang M., Coons S.W., et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. JClin Oncol 2012, 30:3065-3070.
8. Gutin P.H., Wilson C.B., Kumar A.R., et al. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 1975, 35:1398-1404.
9. Prados M.D., Scott C., Curran W.J., Nelson D.F., Leibel S., Kramer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. JClin Oncol 1999, 17:3389-3395.
10. Hildebrand J., De Witte O., Sahmoud T. Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine - a phase-II study. JNeurooncol 1998, 37:155-160.
11. Wick W., Puduvalli V.K., Chamberlain M.C., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. JClin Oncol 2010, 28:1168-1174.
12. Batchelor T.T., Mulholland P., Neyns B., et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. JClin Oncol 2013, 31:3212-3218.
13. Dachsel J.C., Ngok S.P., Lewis-Tuffin L.J., et al. The Rho guanine nucleotide exchange Factor Syx regulates the balance of Dia and ROCK activities to promote polarized-cancer-cell migration. Mol Cell Biol 2013, 33:4909-4918.
14. http://clinicaltrials.gov/show/NCT01737346.
15. Glas M., Bahr O., Felsberg J., et al. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 2011, 70:445-453.
16. Goerne R., Bogdahn U., Hau P. Procarbazine - a traditional drug in the treatment of malignant gliomas. Curr Med Chem 2008, 15:1376-1387.
17. Yung W.K., Albright R.E., Olson J., et al. Aphase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.
18. Ruiz J., Case D., Enevold G., et al. Aphase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. JNeurooncol 2012, 106:611-617.
19. Shibui S., Narita Y., Mizusawa J., et al. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol 2013, 71:511-521.
20. Fine H.A., Dear K.B., Loeffler J.S., Black P.M., Canellos G.P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585-2597.
21. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
22. Party MRCBTW Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. JClin Oncol 2001, 19:509-518.
23. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
24. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. NEngl J Med 2005, 352:997-1003.
25. Brennan C.W., Verhaak R.G., McKenna A., et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477.
26. Clarke J.L., Iwamoto F.M., Sul J., et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. JClin Oncol 2009, 27:3861-3867.
27. Balducci M., Fiorentino A., De Bonis P., et al. Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. Strahlenther Onkol 2013, 189:926-931.
28. Malkoun N., Chargari C., Forest F., et al. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. JNeurooncol 2012, 106:127-133.
29. Roldan Urgoiti G.B., Singh A.D., Easaw J.C. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. JNeurooncol 2012, 108:173-177.
30. Darlix A., Baumann C., Lorgis V., et al. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res 2013, 33:3467-3474.
31. Brada M., Stenning S., Gabe R., et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. JClin Oncol 2010, 28:4601-4608.
32. Franceschi E., Omuro A.M., Lassman A.B., Demopoulos A., Nolan C., Abrey L.E. Salvage temozolomide for prior temozolomide responders. Cancer 2005, 104:2473-2476.
33. Glantz M., Chamberlain M., Liu Q., Litofsky N.S., Recht L.D. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003, 97:2262-2266.
34. Wick W., Platten M., Meisner C., et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13:707-715.
35. Malmstrom A., Gronberg B.H., Marosi C., et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012, 13:916-926.
36. Levin N., Gomori J.M., Siegal T. Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. Neurology 2004, 63:354-356.
37. Beauchesne P. Fotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas. Cancers 2012, 4:77-87.
38. Chamberlain M.C., Johnston S.K. Salvage therapy with single agent bendamustine for recurrent glioblastoma. JNeurooncol 2011, 105:523-530.
39. Shih K., Bacha J.A., Brown D., et al. MR-028. Phase I/II study of VAL-083 in patients with recurrent malignant glioma or progressive-secondary brain tumor. Neuro Oncol 2013, 15:ii75-iii84.
40. Chamberlain M.C., Tsao-Wei D.D. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 2004, 100:1213-1220.
41. Wainwright D.A., Dey M., Chang A., Lesniak M.S. Targeting Tregs in malignant brain cancer: overcoming IDO. Front Immunol 2013, 4:116.
42. Doloff J.C., Waxman D.J. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012, 72:1103-1115.
43. Jeyapalan S., Boxerman J., Donahue J., et al. Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group study. Am J Clin Oncol 2013, [Epub ahead of print].
44. Drappatz J., Brenner A., Wong E.T., et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res 2013, 19:1567-1576.
45. Grossmann K.F., Colman H., Akerley W.A., et al. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. JNeurooncol 2012, 110:257-264.
46. Bouffet E., Jakacki R., Goldman S., et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. JClin Oncol 2012, 30:1358-1363.
47. Biassoni V., Casanova M., Spreafico F., Gandola L., Massimino M. Acase of relapsing glioblastoma multiforme responding to vinorelbine. JNeurooncol 2006, 80:195-201.
48. Massimino M., Biassoni V., Gandola L., et al. Nimotuzumab and vinorelbine concomitantly to radiation and as maintenance for diffuse pontine glioma in childhood: promising results on a series of 20 patients. Neuro Oncol 2012, 14(Suppl. 1):i26-i32. abstract PG-04.
49. Fulton D., Urtasun R., Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. JNeurooncol 1996, 27:149-155.
50. Chamberlain M.C., Wei-Tsao D.D., Blumenthal D.T., Glantz M.J. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer 2008, 112:2038-2045.
51. Prados M.D., Lamborn K., Yung W.K., et al. Aphase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006, 8:189-193.
52. Leonard A., Wolff J.E. Etoposide improves survival in high-grade glioma: a meta-analysis. Anticancer Res 2013, 33:3307-3315.
53. Wolff J.E., Trilling T., Molenkamp G., Egeler R.M., Jurgens H. Chemosensitivity of glioma cells invitro: a meta analysis. JCancer Res Clin Oncol 1999, 125:481-486.
54. Massimino M., Spreafico F., Cefalo G., et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. JClin Oncol 2002, 20:4209-4216.
55. Grossman S.A., Wharam M., Sheidler V., et al. Phase II studyof continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. JClin Oncol 1997, 15:2596-2603.
56. Franceschi E., Cavallo G., Scopece L., et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer 2004, 91:1038-1044.
57. Cloughesy T.F., Gobin Y.P., Black K.L., et al. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. JNeurooncol 1997, 35:121-131.
58. Charest G., Sanche L., Fortin D., Mathieu D., Paquette B. Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain. JNeurooncol 2013, 115:365-373.
59. Miura Y., Takenaka T., Toh K., et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano 2013, 7:8583-8592.
60. Yang F.Y., Horng S.C. Chemotherapy of glioblastoma by targeted liposomal platinum compounds with focused ultrasound. Conf Proc IEEE Eng Med Biol Soc 2013, 2013:6289-6292.
61. Yang W., Barth R.F., Huo T., et al. Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors. Radiat Oncol 2014, 9:25.
62. White E., Bienemann A., Pugh J., et al. An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma. JNeurooncol 2012, 108:77-88.
63. http://commons.wikimedia.org/wiki/File%3AProtein_VEGFA_PDB_1bj1.png.
64. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
65. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
66. Vredenburgh J.J., Cloughesy T., Samant M., et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 2010, 15:1329-1334.
67. Kil W.J., Tofilon P.J., Camphausen K. Post-radiation increase in VEGF enhances glioma cell motility invitro. Radiat Oncol 2012, 7:25.
68. von Baumgarten L., Brucker D., Tirniceru A., et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 2011, 17:6192-6205.
69. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. JClin Oncol 2007, 25:4722-4729.
70. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. JClin Oncol 2009, 27:740-745.
71. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. JClin Oncol 2009, 27:4733-4740.
72. Zhang G., Huang S., Wang Z. Ameta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. JClin Neurosci 2012, 19:1636-1640.
73. Wong E.T., Gautam S., Malchow C., Lun M., Pan E., Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. JNatl Compr Canc Netw 2011, 9:403-407.
74. Reardon D.A., Desjardins A., Peters K.B., et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. JNeurooncol 2012, 107:155-164.
75. Thompson E.M., Dosa E., Kraemer D.F., Neuwelt E.A. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery 2010, 67:87-93.
76. Reardon D.A., Desjardins A., Vredenburgh J.J., et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009, 101:1986-1994.
77. Desjardins A., Reardon D.A., Coan A., et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012, 118:1302-1312.
78. Verhoeff J.J., Lavini C., van Linde M.E., et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 2010, 21:1723-1727.
79. Taal W., Oosterkamp H.M., Walenkamp A.M., Beerepoot L.V., Hanse M., Van den Bent M.J. Arandomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. JClin Oncol 2013, 31.
80. http://clinicaltrials.gov/ct2/show/NCT01290939.
81. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. JClin Oncol 2008, 26:4672-4678.
82. Rini B.I., Halabi S., Rosenberg J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. JClin Oncol 2010, 28:2137-2143.
83. Dahlberg S.E., Sandler A.B., Brahmer J.R., Schiller J.H., Johnson D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. JClin Oncol 2010, 28:949-954.
84. Jain L., Sissung T.M., Danesi R., et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. JExp Clin Cancer Res 2010, 29:95.
85. Lombardi G., Zustovich F., Farina P., et al. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Anti-cancer Drugs 2013, 24:90-97.
86. Pope W.B., Qiao X.J., Kim H.J., et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. JNeurooncol 2012, 108:491-498.
87. Boxerman J.L., Zhang Z., Safriel Y., et al. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro Oncol 2013, 15:945-954.
88. Iwamoto F.M., Abrey L.E., Beal K., et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73:1200-1206.
89. de Groot J.F., Fuller G., Kumar A.J., et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010, 12:233-242.
90. Keunen O., Johansson M., Oudin A., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011, 108:3749-3754.
91. Tabatabai G., Felsberg J., Sabel M. Bevacizumab failure in glioblastomas. JClin Oncol 2012, 30(Suppl.). abstract 2067.
92. Zuniga R.M., Torcuator R., Jain R., et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. JNeurooncol 2010, 99:237-242.
93. de Groot J.F., Lamborn K.R., Chang S.M., et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. JClin Oncol 2011, 29:2689-2695.
94. de Groot J.F., Piao Y., Tran H., et al. Myeloid biomarkersassociated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 2011, 17:4872-4881.
95. Kreisl T.N., Smith P., Sul J., et al. Continuous daily sunitinib for recurrent glioblastoma. JNeurooncol 2013, 111:41-48.
96. Nabors L.B., Supko J.G., Rosenfeld M., et al. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 2011, 13:1324-1330.
97. Zustovich F., Landi L., Lombardi G., et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res 2013, 33:3487-3494.
98. Galanis E., Anderson S.K., Lafky J.M., et al. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 2013, 19:4816-4823.
99. Lee E.Q., Kuhn J., Lamborn K.R., et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol 2012, 14:1511-1518.
100. Muhic A., Poulsen H.S., Sorensen M., Grunnet K., Lassen U. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. JNeurooncol 2013, 111:205-212.
101. Brandes A.A., Stupp R., Hau P., et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 2010, 46:348-354.
102. Kreisl T.N., McNeill K.A., Sul J., Iwamoto F.M., Shih J., Fine H.A. Aphase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol 2012, 14:1519-1526.
103. Reardon D.A., Groves M.D., Wen P.Y., et al. Aphase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res 2013, 19:900-908.
104. Wen P.Y., Prados M., Schiff D., et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). JClin Oncol 2010, 28(Suppl.). abstract 2006.
105. Kelley R.K. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. JClin Oncol 2013, 31:3483-3486.
106. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
107. Kamoun W.S., Ley C.D., Farrar C.T., et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. JClin Oncol 2009, 27:2542-2552.
108. Dunn G.P., Rinne M.L., Wykosky J., et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012, 26:756-784.
109. Vitucci M., Hayes D.N., Miller C.R. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer 2011, 104:545-553.
110. Beroukhim R., Getz G., Nghiemphu L., et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007, 104:20007-20012.
111. Network TCGAR Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
112. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
113. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
114. Verhaak R.G., Hoadley K.A., Purdom E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
115. Vivanco I., Robins H.I., Rohle D., et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2012, 2:458-471.
116. Barkovich K.J., Hariono S., Garske A.L., et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov 2012, 2:450-457.
117. Ji H., Zhao X., Yuza Y., et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006, 103:7817-7822.
118. Eisenstat D.D., Nabors L.B., MW P., PJ R., Shapiro W.R. Aphase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. JClin Oncol 2011, 20(Suppl.). abstract 2010.
119. Hasselbalch B., Lassen U., Hansen S., et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010, 12:508-516.
120. Solomon M.T., Selva J.C., Figueredo J., et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 2013, 13:299.
121. Westphal M., Bach F. Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temozolamide. JClin Oncol 2012, 30(Suppl.). abstract 2033.
122. Brennan C., Momota H., Hambardzumyan D., et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009, 4:e7752.
123. Xu P., Qiu M., Zhang Z., et al. The oncogenic roles of Notch1 in astrocytic gliomas invitro and invivo. JNeurooncol 2010, 97:41-51.
124. Tolcher A.W., Messersmith W.A., Mikulski S.M., et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. JClin Oncol 2012, 30:2348-2353.
125. Jun H.J., Bronson R.T., Charest A. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells 2014, 32:338-348.
126. Joo K.M., Jin J., Kim E., et al. MET signaling regulates glioblastoma stem cells. Cancer Res 2012, 72:3828-3838.
127. Assanah M.C., Bruce J.N., Suzuki S.O., Chen A., Goldman J.E., Canoll P. PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain. Glia 2009, 57:1835-1847.
128. Sun Y., Zhang W., Chen D., et al. Aglioma classification scheme based on coexpression modules of EGFR and PDGFRA. Proc Natl Acad Sci USA 2014, 111:3538-3543.
129. Huang Y., Hoffman C., Rajappa P., et al. Oligodendrocyte progenitor cells promote neo-vascularization in glioma bydisrupting the blood brain barrier. Cancer Res 2014, 74:1011-1021.
130. Reardon D.A., Dresemann G., Taillibert S., et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 2009, 101:1995-2004.
131. Balana C., Gil M.J., Perez P., et al. Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study. Target Oncol 2014, [Epub ahead of print].
132. Reardon D.A., Vredenburgh J.J., Desjardins A., et al. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. JNeurooncol 2012, 108:499-506.
133. Narita Y., Nagane M., Mishima K., Huang H.J., Furnari F.B., Cavenee W.K. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 2002, 62:6764-6769.
134. Wang H., Wang H., Zhang W., Huang H.J., Liao W.S., Fuller G.N. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 2004, 84:941-951.
135. Wen P.Y., Lee E.Q., Reardon D.A., Ligon K.L., Alfred Yung W.K. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 2012, 14:819-829.
136. Cloughesy T.F., Yoshimoto K., Nghiemphu P., et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008, 5:e8.
137. Chinnaiyan P., Won M., Wen P.Y., et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2013, 86:880-884.
138. Masui K., Tanaka K., Akhavan D., et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 2013, 18:726-739.
139. Singh D., Chan J.M., Zoppoli P., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
140. http://clinicaltrials.gov/ct2/show/NCT01975701.
141. Parker B.C., Annala M.J., Cogdell D.E., et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. JClin Invest 2013, 123:855-865.
142. Dahiya S., Emnett R.J., Haydon D.H., et al. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 2014, 16:318-319.
143. Kleinschmidt-DeMasters B.K., Aisner D.L., Birks D.K., Foreman N.K. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013, 37:685-698.
144. Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. NEngl J Med 2012, 367:1694-1703.
145. Nicolaides T.P., Li H., Solomon D.A., et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 2011, 17:7595-7604.
146. Dasgupta T., Yang X., Hashizume R., et al. Survival advantage with radiation combined with a selective BRAFV600E inhibitor in an orthotopic, intracranial model of BRAFV600E-mutated high-grade gliomas. Int J Radiat Oncol Biol Phys 2012, 84:S125.
147. Kopetz S., Desai J., Chan E., et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. JClin Oncol 2010, 28(Suppl.). abstract 3534.
148. Prahallad A., Sun C., Huang S., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
149. Agarwal S., Manchanda P., Vogelbaum M.A., Ohlfest J.R., Elmquist W.F. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Disposition 2013, 41:33-39.
150. Grommes C., Oxnard G.R., Kris M.G., et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011, 13:1364-1369.
151. Szerlip N.J., Pedraza A., Chakravarty D., et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 2012, 109:3041-3046.
152. Sottoriva A., Spiteri I., Piccirillo S.G., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013, 110:4009-4014.
153. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823.
154. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
155. Akhavan D., Pourzia A.L., Nourian A.A., et al. De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 2013, 3:534-547.
156. Nathanson D.A., Gini B., Mottahedeh J., et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 2014, 343:72-76.
157. Li L., Puliyappadamba V.T., Chakraborty S., et al. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. Oncogene 2013, [Epub ahead of print].
158. Turcan S., Rohle D., Goenka A., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
159. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. NEngl J Med 2009, 360:765-773.
160. Rohle D., Popovici-Muller J., Palaskas N., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
161. Lu C., Ward P.S., Kapoor G.S., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
162. Turcan S., Fabius A.W., Borodovsky A., et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget 2013, 4:1729-1736.
163. Clozel T., Yang S., Elstrom R.L., et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 2013, 3:1002-1019.
164. Patel R., Shervington L., Lea R., Shervington A. Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma. Brain Res 2008, 1188:173-181.
165. Leshchenko V.V., Kuo P.Y., Jiang Z., Thirukonda V.K., Parekh S. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma. Clin Cancer Res 2014, 20:382-392.
166. Dutoit V., Herold-Mende C., Hilf N., et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012, 135:1042-1054.
167. http://clinicaltrials.gov/ct2/show/NCT00045968.
168. Liu Y., Carlsson R., Ambjorn M., et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. JNeurosci 2013, 33:14231-14245.
169. Chan J.L., Lee S.W., Fraass B.A., et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. JClin Oncol 2002, 20:1635-1642.
170. Piroth M.D., Pinkawa M., Holy R., et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther Onkol 2012, 188:334-339.
171. Dungey F.A., Loser D.A., Chalmers A.J. Replication-dependent radiosensitization of human glioma cells by inhibition ofpoly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008, 72:1188-1197.
172. Barton K.L., Misuraca K., Cordero F., et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One 2013, 8:e77639.
173. Cen L., Carlson B.L., Schroeder M.A., et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol 2012, 14:870-881.
174. http://clinicaltrials.gov/ct2/show/NCT01227434.
175. Lomonaco S.L., Finniss S., Xiang C., et al. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009, 125:717-722.
176. Newlands E.S., Blackledge G.R., Slack J.A., et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992, 65:287-291.
177. Wen P.Y., Schiff D., Cloughesy T.F., et al. It is time to include patients with brain tumors in phase I trials in oncology. JClin Oncol 2011, 29:3211-3213.
178. Massard C., Sandhu S., Blanco M., et al. Toward a better dialogue between neuro-oncologists and phase I investigators. JClin Oncol 2012, 30:562-563. author reply 3-4.
179. Guilfoyle M.R., Weerakkody R.A., Oswal A., et al. Implementation of neuro-oncology service reconfiguration in accordance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiforme. Br J Cancer 2011, 104:1810-1815.
180. Alexander B.M., Wen P.Y., Trippa L., et al. Biomarker-based adaptive trials for patients with glioblastoma-lessons from I-SPY 2. Neuro Oncol 2013, 15:972-978.
181. Wen P.Y. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?. JClin Oncol 2010, 28:1977-1979.
182. Perry J.R., Belanger K., Mason W.P., et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. JClin Oncol 2010, 28:2051-2057.
183. Salmaggi A., Eoli M., Frigerio S., et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. JNeurooncol 2003, 62:297-303.